Press Releases

GlobeNewswire, Inc.

Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period Adjusted EBITDA for Q2 2026 was $95.4 million, an 8.0% increase...

GlobeNewswire, Inc.

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology...

GlobeNewswire, Inc.

Second Quarter Revenue Increased 19% to $8.4 Million Driven by Strong Growth from Direct Patient Services Operating Cash Flow Reached $4.4 Million in First Half of 2026 Conference Call Scheduled for Today at 1:00 PM ET SAN FRANCISCO, Aug. 13, 2026...

GlobeNewswire, Inc.

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30...

GlobeNewswire, Inc.

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO Phase 1/2 combination study...

GlobeNewswire, Inc.

Record Quarterly Revenues of $1.26 Billion, a 111% Increase from a Year Ago Excluding Bowers Acquisition, Revenues (non-GAAP) Grew by 60% from a Year Ago1 Quarterly Adjusted EBITDA (non-GAAP) Increased 114% from Prior Year2 Record Total Backlog...

GlobeNewswire, Inc.

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being...

GlobeNewswire, Inc.

SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people...

GlobeNewswire, Inc.

FORT LAUDERDALE, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery...

GlobeNewswire, Inc.

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial of Iopofosine I 131 in...

GlobeNewswire, Inc.

SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system...

GlobeNewswire, Inc.

Second quarter 2026 GAAP net investment income (“NII”) of $3.5 million, or $0.15 per weighted average share WEST PALM BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Flower Capital Inc. (Nasdaq: AFCG) (“AFC,” or the “Company”) today...

GlobeNewswire, Inc.

KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products,...

GlobeNewswire, Inc.

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support Clinical recovery and biologic readouts...

GlobeNewswire, Inc.

- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared to prefilled syringes - -...

GlobeNewswire, Inc.

Registrational RESET-Myositis® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher...

GlobeNewswire, Inc.

- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess Halneuron® reduction in pain over three months of...

GlobeNewswire, Inc.

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge FDA clearance of the...

GlobeNewswire, Inc.

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 study Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor A newly-formed portfolio company with funds advised...

GlobeNewswire, Inc.

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Pivotal phase 3 clinical data published in The Lancet Oncology demonstrated a...